Pembrolizumab Better Increases Progression-Free Survival in Advanced Melanoma Patients

July 9, 2015

In a phase II trial, patients with advanced melanoma who saw disease progression while on ipilimumab and a BRAF or MEK inhibitor, if tested positive for BRAF V600 mutation, who received treatment with pembrolizumab had longer progression-free survival than those who received chemotherapy instead of pembrolizumab. Pembrolizumab is a PD-1 inhibitor. PD-1 inhibitors work by stimulating the body’s own immune system to fight tumors.  Read more here.

To learn more about treatments for melanoma, visit My PearlPoint.

If you or a loved one has been diagnosed with melanoma, sign up for a FREE dashboard on My PearlPoint to receive personalized information and resources.